Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q3 2019 · 10-Q
Revenue$14.50M$14.50M+84.1% vs Q3 2018 Net Income-$2.59M-$2.59MN/M vs Q3 2018 EPS Diluted-$0.05-$0.05N/M vs Q3 2018 Operating Income-$2,914,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$12,884,000N/M Margins · derivedOperating margin-20.1%+79.0 pt vs Q3 2018
Net margin-17.9%+60.3 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 12, 2019 · 43 d after period end